Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Net Income (2023 - 2025)

Mangoceuticals' Net Income history spans 3 years, with the latest figure at -$2.8 million for Q4 2025.

  • On a quarterly basis, Net Income fell 42.12% to -$2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.6 million, a 137.08% decrease, with the full-year FY2025 number at -$20.6 million, down 137.08% from a year prior.
  • Net Income hit -$2.8 million in Q4 2025 for Mangoceuticals, up from -$7.6 million in the prior quarter.
  • Over the last five years, Net Income for MGRX hit a ceiling of -$1.8 million in Q3 2023 and a floor of -$7.6 million in Q3 2025.
  • Historically, Net Income has averaged -$3.2 million across 3 years, with a median of -$2.5 million in 2023.
  • Biggest five-year swings in Net Income: grew 24.12% in 2024 and later tumbled 281.0% in 2025.
  • Tracing MGRX's Net Income over 3 years: stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then tumbled by 42.12% to -$2.8 million in 2025.
  • Business Quant data shows Net Income for MGRX at -$2.8 million in Q4 2025, -$7.6 million in Q3 2025, and -$5.4 million in Q2 2025.